3/4/2014 7:55:48 AM
Oxygen Biotherapeutics announced Tuesday that federal regulators have lifted their clinical hold on the Morrisville company’s treatment for traumatic brain injuries. The move by the Food and Drug Administration allows Morrisville-based Oxygen Bio to move ahead with clinical development of Oxycyte. The company has partnered with Wilmington-based PPD to complete the second-phase of clinical trials of Oxycyte. In September, Oxygen Bio submitted data from two animal studies that were designed to address FDA concerns about the drug. The FDA informed Oxygen Bio of the results of its review on Friday.
Help employers find you! Check out all the jobs and post your resume.
comments powered by